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Abstract   1 
Tumor-infiltrating lymphocytes (TILs) have shown a promising prognostic value in many epithelial 2 
cancers. We sought to assess the prognostic value of TILs in a multicenter cohort of early oral tongue 3 
squamous cell carcinoma (OTSCC). The percentage of TILs was assessed on the surgical resection 4 
slides stained with hematoxylin and eosin (HE). The assessment of TILs was performed in the stromal 5 
compartment and in the intra-epithelial compartment (at the invasive front and at the center of the 6 
tumor). We followed the method that was described recently by the International Immuno-Oncology 7 
Biomarker Working Group for the assessment of TILs. A total of 308 cases from the five Finnish 8 
university hospitals and from A.C. Camargo Cancer Center, São Paulo, Brazil were included. We 9 
found a promising prognostic value for stromal TILs at the invasive front in the multivariable analysis 10 
with a hazard ratio of 2.61 (95%CI 1.77-3.83; P<0.001) for overall survival, 1.99 (95%CI 1.07-3.69; 11 
P=0.040) for disease-specific survival, and 1.94 (95%CI 1.14-3.29; P=0.020) for disease-free 12 
survival. In conclusion, evaluation of TILs is simple and can aid in identifying the high-risk cases of 13 
early OTSCC. The method introduced by the International Immuno-Oncology Biomarker Working 14 
Group can be used for standardized determination of TILs in early OTSCC.    15 
 16 
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Introduction                                                                    1 
Oral tongue squamous cell carcinoma (OTSCC) is associated with worse survival compared to SCC 2 
of other sites of the oral cavity 1. The current prognostic biomarkers of early-stage OTSCC do not 3 
provide optimal risk stratification 2. Therefore, searching for "informative, simple and reliable" 4 
biomarkers is of great importance, since those biomarkers will form a cornerstone for individualized 5 
treatment. The role of tumor microenvironment in cancer development and prognosis has evoked 6 
increasing interest among cancer researchers in recent years. Immune cells comprise one component 7 
of the tumor microenvironment and the immune infiltrates associating with tumors have been studied 8 
widely 3, 4.    9 
Pathological prognostication of clinical behavior is usually based on specific histopathologic 10 
features like tumor grade, pattern of invasion and perineural invasion. Recent research indicates that 11 
the immune response is a key player during cancer progression 5. Moreover, an increasing number of 12 
evidence shows immune response to be a viable prognostic marker and, in many cases, even superior 13 
to the TNM classification 6. Therefore, it is suggested that tumor-infiltrating lymphocytes (TILs) or 14 
similar immunoscores should be included in standard pathological classifications 6. However, the 15 
routine pathology report does not evaluate the immune response in OTSCC. Therefore, it is of clinical 16 
importance to find histopathologic criteria that can effectively assess immune response using the 17 
routine hematoxylin and eosin (HE)-stained slides.  18 
The International Immuno-Oncology Biomarker Working Group 7, 8 has recently introduced 19 
guidelines for assessment of TILs in solid tumors using HE-stained sections 7. Growing evidence 20 
highlights the significance of this new method in evaluating the TILs as a determining factor of tumor 21 
biology with special focus on their prognostic/predictive value 8. Although the histological 22 
assessment of TILs in HE-stained samples does not reveal the different subpopulations of 23 
lymphocytes, it may yet prove to be a useful biomarker for assessing tumor behavior. Among the 24 
several advantages of this method is its cost-effectiveness, no requirement of expensive or specific 25 
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tools or antibodies, and easy incorporation into standard pathology report. In this study, we 1 
investigated the significance of TILs as a potential prognostic marker in early OTSCC using a multi-2 
institutional cohort that we have used in our previous study 9.     3 
 4 
Material and Methods 5 
Patients: This study included 308 patients (163 men and 145 women) treated for early OTSCC at 6 
one of the five Finnish University Hospitals (Helsinki, Turku, Tampere, Oulu, and Kuopio) or at the 7 
A.C. Camargo Cancer Center, São Paulo, Brazil. The primary treatment of patients in our cohort was 8 
surgical resection. The use of patient samples and the data enquiry were approved by the above-9 
mentioned University hospitals, by the Brazilian Human Research Ethics Committee and by the 10 
Finnish National Supervisory Authority for Welfare and Health (VALVIRA). 11 
Scoring of TILs: A training session was arranged to familiarize the observers with the scoring 12 
criteria. We evaluated TILs according to a scoring method introduced recently by the International 13 
Immuno-Oncology Biomarkers Working Group 7. In brief, intra-tumoral TILs were scored as the 14 
percentage of tumor islands occupied by lymphocytes; and stromal TILs were defined as the 15 
percentage of stroma occupied by lymphocytes. Any stromal area that did not relate directly to the 16 
tumor was not included in the estimation of TILs. Moreover, areas of fibrosis or central necrosis were 17 
not included in the assessment of TILs 7. The percentage of TILs was assessed in two regions of each 18 
sample (at the invasive front and at the central part of the tumor). Assessment of TILs was made in 19 
two compartments, the intra-tumoral (i.e. intra-epithelial) and the stromal compartment. Tumor slides 20 
were visually scanned by light microscope, and the percentage of TILs at the invasive front was 21 
estimated separately for the intra-tumoral part and for the stromal part. The same scoring method was 22 
used to assess TILs in the central region of the tumor. The TILs working group guidelines 7, 10  has 23 
pointed out “Do not focus on hot spots”. Therefore, the average of TILs in the stromal area was 24 
considered when reporting stromal TILs. Similarly, the average of TILs in the tumor area was 25 
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considered when reporting intra-tumoral TILs. The percentage of TILs was assessed semi-1 
quantitatively as an incremental parameter (e.g. 5%, 10%, 20%, 30%...) as previously described 7, 10. 2 
For example, 50% stromal TILs indicates that half of the stromal area is occupied by infiltrating 3 
lymphocytes. The sample was scanned at low magnification (with 5-10× objectives), then the average 4 
percentage of TILs across microscopic fields was estimated at higher magnification (with 20-40× 5 
objectives). At least five fields were evaluated to assess the average of TILs. We used full untrimmed 6 
sections from the resected tumors as has been recommended 10. At least one representative section 7 
(4-5 µm) was available for each case included in our study. Low-quality tumor sections (e.g. those 8 
without tumor-stroma interface) were excluded from our cohort.    9 
The scoring of TILs was performed using HE-stained slides (Fig. 1). Evaluation of TILs was 10 
conducted by an independent researcher (IH); all sections were reviewed by a senior researcher (IB), 11 
and then we calculated the degree of agreement between the observers.  12 
Data analysis: Cohens’s kappa was used to estimate the inter-rater reliability between the observers 13 
in classifying the tumors into low and high TILs. Cross-tabulation and Chi-square test was also 14 
applied to evaluate the associations between TILs and age, gender, cTNM, WHO grade and PNI. 15 
Univariable and multivariable analyses were conducted to evaluate the associations between 16 
explanatory variables and the overall survival (OS), disease-specific survival (DSS) and disease-free 17 
survival (DFS) using the Cox regression model 11. In multivariable analysis, only those variables that 18 
appeared statistically significant in the univariable analysis were included for the estimated models. 19 
Therefore, TILs (low vs high) was analysed as the main explanatory variable; and age, stage, gender, 20 
WHO grade and perineural invasion (PNI) were used as covariates in the multivariable models. 21 
Hazard ratios (HR) and 95% confidence intervals (95%CI) were reported for both univariable and 22 
multivariable analyses. The proportional hazards assumptions of Cox regression were met by the 23 
data. Kaplan-Meier survival curves were used to describe the OS, DSS and DFS based on TILs. We 24 
used log-rank test to evaluate the statistical significance between the survival curves. The statistical 25 
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analyses were performed using IBM SPSS Statistics (version 24) and MedCalc (version 18). A P 1 
value of < 0.05 (two sided) was considered as statistically significant. 2 
 3 
Results  4 
A total of 308 patients clinically classified as T1N0M0 (122 cases) or T2N0M0 (186 cases) were 5 
included in this study.  6 
The presence of TILs in the stromal part (i.e. sTILs) ranged from 1% to 95%, and in the intra-7 
tumoral/intra-epithelial part (i.e. iTILs) ranged from 0% to 25%. Different cutoff points (5%, 10%, 8 
20% ...etc) were applied to stratify the tumors as containing low or high TILs. The cutoff point that 9 
was clinically most relevant was found to be 20% (i.e. low TILs ≤ 20%; high TILs > 20%) at the 10 
invasive front. Fifty-one tumors (16.6%) had low TILs and 257 tumors (83.4%) had high TILs. The 11 
relationship between sTIL and the recorded clinicopathologic features is summarized in Table 1. 12 
There was a statistically significant association between sTILs and iTILs (P = 0.021). No association 13 
was found between sTILs and age, gender, cTNM stage, or WHO grade (P > 0.05). sTILs showed an 14 
association with perineural invasion (P = 0.025). We found a moderate agreement between the 15 
observers in classifying the tumors into low TILs or high TILs (Cohen’s kappa = 0.64).   16 
In the univariable analysis (Table 2), low sTILs (≤ 20%) at the invasive front was found as an 17 
adverse prognostic factor for OS (HR 2.46, 95% CI 1.70-3.57, P < 0.001), associated with high cancer 18 
mortality (DSS HR 2.02, 95%CI 1.11-3.66, P = 0.021) and worse DFS (HR 1.93, 95%CI 1.16-3.22, 19 
P = 0.011). While age of the patient was also associated with OS, DSS and DFS (Table 2), the 20 
remaining variables (gender, stage, grade and perineural invasion) were insignificant to be considered 21 
as factors for prognostication. These significant relationships between sTILs and OS, DSS or DFS 22 
are exemplified in the Kaplan-Meier curves (Fig 2 A, B, and C). In multivariable analysis (Table 2), 23 
sTILs showed a promising prognostic value for prediction of OS (HR 2.61, 95%CI 1.77-3.83; P < 24 
0.001), DSS (HR 1.99, 95%CI 1.07-3.69; P = 0.040), and DFS (HR 1.94, 1.14-3.29; P = 0.020).  25 
8 
 
Intra-tumoral infiltrating lymphocytes did not show a significant prognostic value in 1 
univariable analyses of OS (HR 1.14, 95%CI 0.76-1.68; P = 0.51), DSS (HR 1.06, 95%CI 0.57-1.94; 2 
P = 0.863) or DFS (HR 1.06, 95%CI 0.63-1.78; P = 0.834). The insignificant prognostic values of 3 
intra-tumoral infiltrating lymphocytes were confirmed in the multivariable analyses of OS (HR 1.05, 4 
0.71-1.55; P = 0.818), DSS (HR 1.19, 95%CI 0.63-2.22; P = 0.594) and DFS (HR 1.09, 95%CI 0.64-5 
1.85; P = 0.761).  6 
 7 
Discussion   8 
For clinicians, it is a dilemma to identify those cases of early OTSCC that will potentially have an 9 
aggressive behavior and would thus benefit from chemoradiotherapy and/or neck dissection. Many 10 
factors will determine tumor behavior and risk of poor survival. Of these factors, immune response 11 
has been shown to possess a fundamental role in identifying aggressive tumors 6. In this study, we 12 
used the HE-stained slides from surgical specimens to evaluate TILs in a multicenter series of early 13 
OTSCC and we found that tumors with low percentage of stromal TILs (≤ 20%) at the invasive front 14 
have a significantly poor survival (overall, disease-specific and disease-free).  15 
 As the current method of evaluating TILs was based on the use of routine H-E slides, it will 16 
be possible to assess them routinely in the daily practice of pathologists and will provide a better 17 
histopathologic prognostication based on immune response. Such prognostication may be useful for 18 
clinical decision-making including, for example, selecting early-stage OTSCC cases for 19 
multimodality treatments. Recent research highlighted the role of the immune cells in modulating 20 
cancer invasion and metastasis 12. Therefore, the immune response is assumed to influence the clinical 21 
behavior of tumors. In fact, tumors of the same clinical stage and/or same histopathologic grade may 22 
have extremely variable immune responses 6. Thus, the immunological heterogeneity of early OTSCC 23 
can be utilized to classify cases into low-risk and high-risk groups. 24 
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Recently, we have systematically reviewed the prognostic value of all immune checkpoints 1 
that have been studied in oral squamous cell carcinoma  13. We noted that the currently available body 2 
of evidence still require further research and none of the studied immune biomarkers can be approved 3 
for prognostication in daily practice 13. In addition, previous studies have used a specific 4 
immunohistochemical staining which is not routinely ordered by the pathologists. In our previous 5 
research, we evaluated the lymphocytic host response (LHR) according to criteria described in the 6 
histologic risk score 14 and we reported a low prognostic value of that criteria for prognostication of 7 
early OTSCC 15. Noteworthy, LHR was divided into three categories (strong, intermediate or weak) 8 
without quantitative measurement of the immune response. On the other hand, the International 9 
Immuno-Oncology Biomarkers Working Group has indicated that assessment of TILs should be done 10 
as a continuous semiquantitative variable and did not determine risk threshold between high and low 11 
TILs in early OTSCC 7.  12 
Currently, a method for overall assessment of TILs (i.e. using HE-stained slides) after 13 
neoadjuvant treatment of OTSCC has not yet been established. In cases with neoadjuvant therapy 14 
determining the area of the residual tumor to be used for evaluation of TILs requires further research 15 
16. A small and/or superficial preoperative biopsy of oral cancer might also be a problematic as it may 16 
not include the most important area for assessment of TILs (i.e. within the borders of the invasive 17 
tumor). Such limitation of biopsies of oral cancer has been noted during the assessment of other 18 
prognostic features 17. Therefore, it is necessary to consider having a representative sample that is 19 
deep enough including the invasive front for the assessment of TILs.      20 
Recently, there is a worldwide research effort to standardize determination of TILs. Many 21 
studies have reported that a strong lymphocytic infiltration associates with favorable clinical outcome 22 
of different tumors including those of head and neck 18-20. Such favorable outcome could be due to 23 
the destruction of cancer cells and anti-tumor effect of the immune response 21. In conclusion, 24 
assessment of TILs has a reliable prognostic value in early OTSCC. The method introduced recently 25 
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by the International Immuno-Oncology Biomarkers Working Group is simple, cost-effective and can 1 
be easily included in the pathology report. To the best of our knowledge, this is the first multicenter 2 
study on early OTSCC applying the new criteria for evaluation of TILs. Our finding on TILs can be 3 
a key step towards the routine measurement of immune-response in early OTSCC and that could 4 
enhance the personalized treatment approach by classifying risk groups based on immune response. 5 
 6 
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Figure legend 1 
Figure 1: Tumor-infiltrating lymphocytes (TILs) were evaluated on full sections of early OTSCC 2 
stained with hematoxylin and Eosin. Representative samples classified as low (≤ 20%) stromal TILs 3 
(A); and high (> 20%) stromal TILs (B). 4 
 5 
Figure 2: Kaplan-Meier curves for stromal TILs with OS (A), DSS (B), and DFS (C). 6 
TILs: Tumor-infiltrating lymphocytes; OS: Overall survival; DSS: Disease-specific survival; DFS: 7 




Table 1: Relationship between tumor-infiltrating lymphocytes (TILs) and clinicopathologic 
characteristics of 308 cases treated for early oral tongue cancer.   
Variable  Total High sTILs Low sTILs P value of 
chi-square 
test 





Age      0.535 
 ≤60  129  110 (85.3) 19 (14.7)  
 >60  179  147 (82.1) 32 (17.9)  
     
Gender    0.363 
 Male 163  133 (81.6) 30 (18.4)  
 Female 145   124 (85.5) 21 (14.5)  
     
cTNM stage*    0.188 
 T1N0M0  122  106 (86.9) 16 (13.1)  
 T2N0M0  186  151 (81.2) 35 (18.8)  
     
Grade (WHO)     0.267 
 Well differentiated 104 89 (85.6) 15 (14.4)  
 Moderately differentiated 129 110 (85.3) 19 (14.7)  
 Poorly differentiated  75  58 (77.3) 17 (22.7)  
     
PNI    0.025 
 Absent  267   228 (85.4)  39 (14.6)  
 Present   41   29 (70.7)  12 (29.3)   
     
iTILs    0.021 
 High 245 198 (80.8) 47 (19.2)  
 Low   63  59 (93.7)  4 (6.3)  
* cTNM stage refers to the 7th edition of AJCC staging manual as our cases were treated before 2017.  





Table 2: Univariable and multivariable analyses of 308 cases treated for early OTSCC. The analyses 
include overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) for tumor-
infiltrating lymphocytes (TILs) and the adjusting variables.  
Variable  Univariable analysis 
OS  DSS  DFS 
HR (95%CI)  HR (95%CI)  HR (95%CI)  
Age        
 ≤60 1  1  1 
 >60 2.17 (1.55-3.03)  1.89 (1.11-3.21)  1.76 (1.13-2.75) 
 P < 0.001  P = 0.020  P = 0.013 
Gender      
 Male 1  1  1 
 Female 0.79 (0.57-1.08)  1.20 (0.73-1.97)  1.10 (0.72-1.68) 
 P = 0.134  P = 0.464  P = 0.651 
Stage      
 T1N0M0 1  1  1 
 T2N0M0 1.26 (0.90-1.76)  1.47 (0.86-2.51)  0.89 (0.58-1.37) 
 P = 0.177  P = 0.164  P = 0.603 
Grade (WHO)       
 Well differentiated 1  1  1 
 Moderately differentiated 1.36 (0.95-1.96)  1.70 (093-3.11)  1.08 (0.66-1.77) 
 P = 0.094  P = 0.085  P = 0.748 
 Poorly differentiated 1.10 (0.71-1.69)  1.58 (0.79-3.16)  1.25 (0.72-2.16) 
 P = 0.655   P = 0.196  P = 0.435 
PNI      
 Absent 1  1  1 
 Present  1.32 (0.86-2.01)  1.32 (0.67-2.59)  1.38 (0.78-2.44) 
 P = 0.204  P = 0.424  P = 0.270 
iTILs      
 High 1  1  1 
 Low 1.14 (0.76-1.68)  1.06 (0.57-1.94)  1.06 (0.63-1.78) 
 P = 0.51  P = 0.863  P = 0.834 
sTILs      
 High 1  1  1 
 Low 2.46 (1.70-3.57)  2.02 (1.11-3.66)  1.93 (1.16-3.22) 
 P < 0.001  P = 0.021  P = 0.011 
 
Multivariable analysis 
Age       
 ≤60 1  1  1 
 >60 2.48 (1.74-3.52)  2.05 (1.18-3.57)  1.85 (1.16-2.94) 
 P = 0.001  P = 0.009  P = 0.008 
sTILs      
 High 1  1  1 
 Low  2.61 (1.77-3.83)  1.99 (1.07-3.69)  1.94 (1.14-3.29) 
 P < 0.001  P = 0.040  P = 0.020 
Multivariable models were adjusted fort gender, stage, grade, and PNI.  
iTILs: intra-tumoral TILs; sTILs: stromal TILs.  
